S
Sol-Gel Technologies Ltd D
D
SLGL
78.420
USD
-0.16
(-0.20%)
قبل الجلسة·81.050USD+2.630(+3.35%)
حجم التداول
978
الربح لكل سهم
-5
العائد الربحي
-
P/E
-14
حجم السوق
256,354,274
المقالات
العنوان: Sol/Gel Technologies Ltd
القطاع: الرعاية الصحية
الصناعة: Biotechnology
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includesSGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease andother rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
















